This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Expert Perspectives on Parkinson's Disease Psychosis: Identification and Management Across Specialties

Expert Perspectives on Parkinson's Disease Psychosis: Identification and Management Across Specialties

Format

Monograph

Time to Complete

1 hour

Released

October 12, 2016

Expires

October 12, 2017
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Acadia Pharmaceuticals, Inc.

Program Description

It is commonly misperceived that minor or “benign” hallucinations are inconsequential in patients with Parkinson’s disease (PD) psychosis, but clinical evidence demonstrates that these portend future, more deleterious hallucinations. Furthermore, caregivers are usually unaware of patients’ psychosis symptoms until they become problematic. Current best-practice treatment guidelines advocate managing PD psychosis with initial consideration of comorbidities and lowering the dosage of the dopaminergic therapy being used to treat the symptoms of PD. However, this approach is usually insufficient, resulting in the need for antipsychotic medictions. No medications are currently approved by the US Food and Drug Administration (FDA) specifically for PD psychosis. Several antipsychotic medications have been used off-label to treat PD psychosis, but these agents demonstrate limited efficacy and/or are associated with safety concerns. Emerging treatments, such as pimavanserin, may overcome these obstacles. When the time comes to select and initiate treatment, shared decision-making (SDM) between clinicians and the patient and/or caregivers contributes to patient satisfaction and often to better clinical outcomes.

Intended Audience

Neurologists/movement disorder specialists, geriatric psychiatrists, long-term care clinicians, and primary care clinicians engaged in the management of patients with PD

Educational Objectives

Upon completion of this educational activity, participants will be better able to:

  • Recognize symptoms associated with PD psychosis
  • Construct individualized, evidence‐based treatment plans for patients with PD psychosis while considering mechanisms of action and safety and efficacy data from clinical trials
  • Utilize the shared decision-making model to enhance clinician communication as well as clinician and patient/caregiver communication with regard to treatment options, adherence, and improving outcomes and quality of life

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Clive Ballard, MD
Professor of Age-Related Diseases
King’s College London
Co-Director, Biomedical Research Unit for Dementia, Institute of Psychiatry
Co-Director, Wolfson Center for Age-Related Diseases
London, England

Dr. Ballard is a consultant, advisory board member, and lead investigator for research funded by Acadia Pharmaceuticals, Inc.

Jennifer G. Goldman, MD, MS
Associate Professor
Section of Parkinson Disease and Movement Disorders
Department of Neurological Sciences
Rush University Medical Center
Chicago, IL

Dr. Goldman is a consultant for Acadia Pharmaceuticals, Inc.; Pfizer Inc.; and Teva Pharmaceutical Industries Ltd.

Stuart Isaacson, MD
Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, FL

Dr. Isaacson is on the speakers’ bureau, a consultant, and lead investigator for research funded by Acadia Pharmaceuticals, Inc.

Jason Kellogg, MD
Chief of Staff and Medical Director, Global Clinical Trials
Newport Bay Hospital
Newport Beach, CA

Dr. Kellogg is on the speakers’ bureaus for Acadia Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.

Faculty Reviewer
Marcello Morgan MD, MPH, CHCP

Associate Medical Director
Haymarket Medical Education
Paramus, NJ

Dr. Morgan has nothing to disclosure with regard to commercial support.

Planners' and Managers' Disclosures

The HME staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Acadia Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact HME at cmequestions@haymarketmedical.com.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue